Table of Contents Table of Contents
Previous Page  313 / 812 Next Page
Information
Show Menu
Previous Page 313 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S309

EW 550

Time to relapse monotherapy and

acquisition in a sample of

schizophrenic patients over 3 years of

follow-up

P. González Rivera

1 ,

, A.J. Benito Ruiz

1

, J. Prados Gomez

1

,

A. Hidalgo Borreguero

2

, M. Soto Laguna

1

, K. Preckler Pe˜na

3

,

S. Bola˜no Mendoza

4

, F.J. González Díaz

5

, V. González Rivera

6

,

M. Fernando-Torija Daza

1

1

Hospital Provincial de la Misericordia, Psiquiatria, Toledo, Spain

2

USMIJ, Psiquiatria, Toledo, Spain

3

Hospital Virgen del Prado, Psiquiatria, Talavera, Spain

4

Hospital 12 de Octubre, Psiquiatria, Madrid, Spain

5

Hospital Virgen de la Salud, Psiquiatria, Toledo, Spain

6

Hospital Sant Joan de Deu, Psiquiatria, Lleida, Spain

Corresponding author.

Introduction

Poor adherence to treatment is one of the main

problems in health care to psychiatric patients. The second-

generation antipsychotics, and the subsequent emergence of the

depot forms (long acting formulations) have facilitated this aspect,

increasing the time to clinical relapse in patients with schizophre-

nia.

Goals

Determine the time to relapse in a clinical sample of

patients diagnosed with schizophrenia treated with paliperidone

palmitate over 3 years. Other objectives include the possible reduc-

tion in hospital admissions, as well as the possible reduction

of psychiatric emergency visits, concomitant medication (ben-

zodiazepines and Biperiden) and the possible increase in drug

monotherapy.

Methodology

This is a study with a sample of 101 patients with

schizophrenia who had started treatment with PP (consecutive

sampling). Quantified variables in the 12 months prior to the

change of PP treatment with variables at 6, 12, 24 and 36 months

after initiation of treatment with PP were compared.

Results and conclusions

At the end of the tracking, 72.22% (73

patients) remained clinically stable, with adequate adherence to

treatment and there have been no clinical relapses. It has obtained a

statistically significant reduction in the use of concomitant medica-

tion, emergency room visits and the average duration of revenues,

with no clinical relapse should occur in patients of the sample in

the second and third year.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.668

EW551

Effects of nicotine abstinence on

clinical symptoms. Study at 3 and

6-months follow-up of outpatients

with schizophrenia

P.A. Sáiz Martinez

1 ,

, S. Al-Halabí

2

, S. Fernández-Artamendi

3

,

L. García-Álvarez

2

, E. Díaz-Mesa

2

, E. Martínez-Santamaría

4

,

G. Florez

5

, M. Arrojo

6

, M.P. García-Portilla

1

, J. Bobes

1

1

Universidad de Oviedo, Área de Psiquiatría - CIBERSAM, Oviedo,

Spain

2

Centro de Investigación Biomédica en Red de Salud Mental-

CIBERSAM., Área de Psiquiatría - Universidad de Oviedo, Oviedo,

Spain

3

Universidad de Oviedo, Facultad de Psicología, Oviedo, Spain

4

Centro Asistencial “AS Burgas”, Unidad de Conductas Adictivas -

Hospital Santa María Nai, Orense, Spain

5

Hospital Santa María Nai, Unidad de Conductas Adictivas, Orense,

Spain

6

Complejo Hospitalario Universitario de Santiago, Psiquiatría,

Santiago de Compostela, Spain

Corresponding author.

Introduction

Tobacco use has been associated with more

excitement and agitation symptoms, greater severity of global psy-

chopathology as measured by the Clinical General Impression (CGI)

Scale, and psychotic symptoms in patients with schizophrenia.

Aim

To assess the effects of nicotine abstinence versus nicotine

maintenance on the clinical symptoms of a sample of outpatients

smokers diagnosed with schizophrenia.

Methods

Sample: 81 outpatients with schizophrenia [72.8%

males; mean age (SD) = 43.35 (8.82)] currently smoking tobacco

[no. of cigarettes (SD) = 27.96 (12.29)]. Desing: non-randomized,

open-label, 6-month follow-up and multi-center study conducted

at 3 sites in Spain (Oviedo, Santiago de Compostela and Orense).

Instruments: Positive and Negative Syndrome Scale (PANSS), Clin-

ical Global Impression for Schizophrenia (CGI-SCH), Hamilton

Depression Rating Scale (HDRS). Antropometric measures: Body

mass index (BMI) and waist circumference. Vital sings: heart rate.

Procedure: Patients were assigned to 2 conditions:

– control group = patients continuing their tobacco use;

– experimental group = patients participated in vareniclina or nico-

tine patches treatment for smoking cessation.

Patients were evaluated at baseline (all patients smoking) and after

3 and 6 months.

Results

No significant differences (

P

>.05) were found between

groups at baseline evaluation. Likewise, there were no significant

differences between smokers and non-smokers after treatment (3

and 6 months follow-up) in their clinical symptomatology (accord-

ing to PANSS, HDRS and CGI-SCH), anthropometric measures and

heart rate.

Conclusions

No significant differences were found in the clinical

symptoms after a period of nicotine abstinence. Therefore, cli-

nicians should motivate and help their patients to quit smoking

(CIBERSAM - FIS PI11/01891).

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.669

EW552

Functional outcome in psychosis is

better determined by negative

symptoms than cognitive impairment

A.M. Sánchez-Torres

1 , 2 , 3 ,

, M.R. Elosúa

2

,

R. Lorente-Ome˜naca

1 , 2 , 3

, L. Moreno-Izco

1 , 3

, V. Peralta

1 , 3

,

M.J. Cuesta

1 , 3

1

Complejo Hospitalario de Navarra, Department of Psychiatry,

Pamplona, Spain

2

Universidad Nacional de Educación a Distancia UNED, Department

of Basic Psychology I, Madrid, Spain

3

IdiSNA, Navarra Institute for Health Research, Pamplona, Spain

Corresponding author.

Introduction

Cognitive impairment is considered the best predic-

tor of functional outcome in psychosis. However, the nature of this

relationship still remains to be determined.

Objective

To ascertain the relationship of negative symptoms and

cognitive impairment with functional outcome in psychosis.

Methods

Ninety patients with a DSM-IV psychotic disorder diag-

nosis and 65 healthy controls were included in the study. We

assessed the predominant negative symptoms over the course of

illness with the Comprehensive Assessment of Symptoms and His-

tory (CASH). Functional outcome was assessed with the Specific

Levels of Functioning (SLOF). Cognition was assessed with a set

of neuropsychological tests, which were normalised to z-scores

(regarding controls’ performance). Then, a Global Cognition Index

(GCI) was obtained as a mean of the cognitive domains assessed:

processing speed, attention, verbal and visual memory, execu-

tive functions, working memory and social cognition. We divided

the sample in four groups, considering the presence/absence of

negative symptoms (cut-off point of 2 in the CASH), and the